Ann Surg Treat Res.  2020 Sep;99(3):180-187. 10.4174/astr.2020.99.3.180.

Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients

• Kim SJ
• Rhu J
• Lee SH
• Kim JM
• Choi GS
• Kim K
• Joh JW

• KMID: 2505493
• DOI: http://doi.org/10.4174/astr.2020.99.3.180

Abstract

Purpose
Tenofovir disoproxil fumarate is accepted as an effective and tolerable drug for treatment of HBV, similar to entecavir. However, there are some concerns about the nephrotoxicity of tenofovir. The aim of this study is to compare the renal-function change of liver recipients who received tenofovir or entecavir for HBV.
Methods
Among 468 patients with HBV who underwent liver transplantation at Samsung Medical Center between January 2008 and December 2015, the patients treated with tenofovir (n = 39) or entecavir (n = 429) were reviewed retrospectively. Baseline characteristics and renal-function change after 1 month, 1 year, and 2 years were compared. Propensity-score matching was performed for 37 patients using tenofovir and 132 patients using entecavir. We also analyzed risk factors of renal dysfunction.
Results
Age, preoperative creatinine, estimated glomerular filtration rate (e-GFR), and hepatic encephalopathy score showed statistical difference between the tenofovir and entecavir groups. The proportion of patients with ‘decreased renal function (e-GFR < 60 mL/min/1.73 m 2 )’ was higher in the tenofovir group than in the entecavir group (33.3% vs. 12.4% at postoperative one year, p < 0.005). After propensity-score matching, there was no statistical difference in preoperative characteristics. Postoperative 1-, 2-, and 3-year e-GFR and creatinine showed no statistical difference in either group. On multivariate analysis, only preoperative high e-GFR showed a protective effect on renal-function change (odds ratio, 0.97; p < 0.001), and there was no aggravating factor.
Conclusion
Tenofovir disoproxil fumarate does not induce renal dysfunction in liver-transplanted patients with HBV more than does entecavir.

Keyword

Entecavir; Renal insufficiency; Tenofovir; Transplantation

Reference

1. Kwak BJ, Kim DG, Han JH, Choi HJ, Bae SH, You YK, et al. Clinical outcome of 1,000 consecutive cases of liver transplantation: a single center experience. Ann Surg Treat Res. 2018; 95:267–277. PMID: 30402445.

2. Sriprayoon T, Mahidol C, Ungtrakul T, Chun-On P, Soonklang K, Pongpun W, et al. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial. Hepatol Res. 2017; 47:E161–E168. PMID: 27176630.

3. Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2012; 35:1317–1325. PMID: 22506503.

4. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl. 2003; 9:741–747. PMID: 12827563.

5. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139:137–147. PMID: 12859163.

6. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45:507–539. PMID: 17256718.

7. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50:661–662. PMID: 19714720.

8. Mathew G, Knaus SJ. Acquired Fanconi's syndrome associated with tenofovir therapy. J Gen Intern Med. 2006; 21:C3–C5. PMID: 17026723.

9. Cho H, Cho Y, Cho EJ, Lee JH, Yu SJ, Oh KH, et al. Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases. Clin Mol Hepatol. 2016; 22:286–291. PMID: 27377911.

10. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010; 51:496–505. PMID: 20673002.

11. Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 2019; 5:30–36. PMID: 30267080.

12. Zhang M, Wang D, Liu H, Li H. Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection. Infect Agent Cancer. 2018; 13:19. PMID: 29977330.

13. Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016; 1:196–206. PMID: 28404092.

14. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006; 17:2974–2984. PMID: 17035611.

15. Weber ML, Ibrahim HN, Lake JR. Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl. 2012; 18:1290–1301. PMID: 22847917.

16. Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, et al. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl. 2013; 19:594–601. PMID: 23447407.

17. Jiménez-Pérez M, Sáez-Gómez AB, Mongil Poce L, Lozano-Rey JM, de la Cruz-Lombardo J, Rodrigo-López JM. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc. 2010; 42:3167–3168. PMID: 20970638.

18. Park J, Jung KS, Lee HW, Kim BK, Kim SU, Kim DY, et al. Effects of entecavir and tenofovir on renal function in patients with hepatitis B virus-related compensated and decompensated cirrhosis. Gut Liver. 2017; 11:828–834. PMID: 28651305.

19. Riveiro-Barciela M, Tabernero D, Calleja JL, Lens S, Manzano ML, Rodríguez FG, et al. Effectiveness and safety of entecavir or tenofovir in a spanish cohort of chronic hepatitis B patients: validation of the page-B score to predict hepatocellular carcinoma. Dig Dis Sci. 2017; 62:784–793. PMID: 28078526.

20. Han Y, Zeng A, Liao H, Liu Y, Chen Y, Ding H. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: a systematic review and meta-analysis. Int Immunopharmacol. 2017; 42:168–175. PMID: 27915131.